CL2020001639A1 - Neurotoxinas para su uso en la minimización de cicatrices. - Google Patents

Neurotoxinas para su uso en la minimización de cicatrices.

Info

Publication number
CL2020001639A1
CL2020001639A1 CL2020001639A CL2020001639A CL2020001639A1 CL 2020001639 A1 CL2020001639 A1 CL 2020001639A1 CL 2020001639 A CL2020001639 A CL 2020001639A CL 2020001639 A CL2020001639 A CL 2020001639A CL 2020001639 A1 CL2020001639 A1 CL 2020001639A1
Authority
CL
Chile
Prior art keywords
neurotoxins
methods
wound
scar
minimization
Prior art date
Application number
CL2020001639A
Other languages
English (en)
Inventor
Sawsan Abushakra
Wajdie Ahmad
Fauad Hasan
Michael Jarpe
Original Assignee
Bonti Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonti Inc filed Critical Bonti Inc
Publication of CL2020001639A1 publication Critical patent/CL2020001639A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos para minimizar cicatrices durante el proceso de cicatrización de heridas. También se describen métodos para mejorar la apariencia de una cicatriz que se forma sobre una herida. Los métodos comprenden administrar una cantidad terapéuticamente efectiva de toxina botulínica subtipo E (BoNT/E) en la proximidad de una herida.
CL2020001639A 2017-12-18 2020-06-17 Neurotoxinas para su uso en la minimización de cicatrices. CL2020001639A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762599972P 2017-12-18 2017-12-18

Publications (1)

Publication Number Publication Date
CL2020001639A1 true CL2020001639A1 (es) 2020-12-04

Family

ID=65441036

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001639A CL2020001639A1 (es) 2017-12-18 2020-06-17 Neurotoxinas para su uso en la minimización de cicatrices.

Country Status (14)

Country Link
US (2) US20190183987A1 (es)
EP (1) EP3727430A1 (es)
JP (2) JP2021506985A (es)
KR (1) KR20210093748A (es)
CN (1) CN111712253A (es)
AU (1) AU2018388588A1 (es)
BR (1) BR112020012466A2 (es)
CA (1) CA3086160A1 (es)
CL (1) CL2020001639A1 (es)
IL (1) IL275451A (es)
MX (1) MX2020006391A (es)
RU (1) RU2020121973A (es)
SG (1) SG11202005745VA (es)
WO (1) WO2019126322A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600221A4 (en) * 2017-03-22 2021-01-13 Bonti, Inc. BOTULINUM NEUROTOXINS FOR USE IN THERAPY
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1128844B1 (en) * 1998-10-27 2006-01-04 Mayo Foundation For Medical Education And Research Botulinum toxins for enhancing wound healing
US20060067950A1 (en) * 2004-09-27 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins for use in wound healing
EP2724725B1 (en) * 2011-06-27 2016-09-07 Sang Duck Kim Pharmaceutical composition for use in treating scars on the skin
WO2015126527A1 (en) * 2014-02-18 2015-08-27 Kaufman-Janette Joely Botulinum neurotoxin for use in the prophylactic treatment of cutaneous wounds
EP3600221A4 (en) * 2017-03-22 2021-01-13 Bonti, Inc. BOTULINUM NEUROTOXINS FOR USE IN THERAPY

Also Published As

Publication number Publication date
WO2019126322A1 (en) 2019-06-27
JP2021506985A (ja) 2021-02-22
US20220395561A1 (en) 2022-12-15
CA3086160A1 (en) 2019-06-27
JP2024014923A (ja) 2024-02-01
CN111712253A (zh) 2020-09-25
RU2020121973A (ru) 2022-01-20
AU2018388588A1 (en) 2020-07-30
BR112020012466A2 (pt) 2020-11-24
EP3727430A1 (en) 2020-10-28
IL275451A (en) 2020-08-31
KR20210093748A (ko) 2021-07-28
SG11202005745VA (en) 2020-07-29
MX2020006391A (es) 2021-04-28
US20190183987A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2020000215A1 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
DOP2017000035A (es) Inhibidores de la proteina quinasa c y metodos de su uso
UA118558C2 (uk) Пептидна сполука
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2020001639A1 (es) Neurotoxinas para su uso en la minimización de cicatrices.
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
ES2721168T3 (es) Agentes para tratar tumores, uso y método de los mismos
ES2721930T3 (es) Composición inmunogénica
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY39188A (es) Imidazopiridazinas como moduladores de il-17
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia